Soleno Therapeutics/$SLNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Ticker
$SLNO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
115
ISIN
US8342033094
Website
SLNO Metrics
BasicAdvanced
$4.2B
-
-$4.65
-2.67
-
Price and volume
Market cap
$4.2B
Beta
-2.67
52-week high
$86.67
52-week low
$39.41
Average daily volume
891K
Financial strength
Current ratio
19.637
Quick ratio
18.432
Long term debt to equity
22.473
Total debt to equity
22.73
Interest coverage (TTM)
-128.22%
Profitability
EBITDA (TTM)
-202.13
Management effectiveness
Return on assets (TTM)
-52.40%
Return on equity (TTM)
-105.54%
Valuation
Price to book
17.39
Price to tangible book (TTM)
17.88
Price to free cash flow (TTM)
-39.675
Free cash flow yield (TTM)
-2.52%
Free cash flow per share (TTM)
-209.83%
Growth
Earnings per share change (TTM)
106.82%
3-year earnings per share growth (CAGR)
-3.69%
10-year earnings per share growth (CAGR)
-38.77%
Bulls say / Bears say
Soleno Therapeutics' DCCR (diazoxide choline) extended-release tablets have received Breakthrough Therapy Designation from the U.S. FDA for treating Prader-Willi syndrome, potentially expediting the drug's approval process. (GlobeNewswire)
The company maintains a strong cash position of $284.7 million as of Q3 2024, providing substantial resources for ongoing research and development. (StockTitan)
Positive clinical trial results for DCCR have demonstrated significant reductions in hyperphagia and improvements in behavioral domains for Prader-Willi syndrome patients, enhancing the drug's market potential. (StockTitan)
The FDA has extended the review period for DCCR by three months to March 27, 2025, potentially delaying the drug's market entry. (StockTitan)
Operating expenses have surged, with R&D expenses reaching $30.1 million and G&A expenses at $49.2 million in Q3 2024, leading to a net loss of $76.6 million for the quarter. (StockTitan)
The company has a history of shareholder dilution, with recent funding rounds potentially impacting existing shareholders' value. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SLNO News
AllArticlesVideos
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
GlobeNewsWire·1 week ago
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
GlobeNewsWire·1 month ago
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Soleno Therapeutics stock?
Soleno Therapeutics (SLNO) has a market cap of $4.2B as of June 30, 2025.
What is the P/E ratio for Soleno Therapeutics stock?
The price to earnings (P/E) ratio for Soleno Therapeutics (SLNO) stock is 0 as of June 30, 2025.
Does Soleno Therapeutics stock pay dividends?
No, Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Soleno Therapeutics dividend payment date?
Soleno Therapeutics (SLNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Soleno Therapeutics?
Soleno Therapeutics (SLNO) has a beta rating of -2.67. This means that it has an inverse relation to market volatility.